SCM
COGT icon

Silverarc Capital Management’s Cogent Biosciences COGT Stock Holding History

Silverarc Capital Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49.6M Sell
1,280,707
-33,482
-3% -$1.17M 5.15% 3
2026
Q1 		$50.6M Buy
1,314,189
+68,935
+6% +$2.55M 5.16% 4
2025
Q4 		$44.2M Buy
1,245,254
+430,179
+53% +$12.1M 6.14% 2
2025
Q3 		$11.7M Buy
+815,075
New +$9.66M 1.58% 19
2025
Q1 		– Sell
-921,137
Closed -$7.18M – 70
2024
Q4 		$7.18M Sell
921,137
-300,225
-25% -$2.99M 1.57% 21
2024
Q3 		$13.2M Buy
1,221,362
+15,148
+1% +$147K 2.96% 9
2024
Q2 		$10.2M Buy
1,206,214
+169,547
+16% +$1.29M 2.4% 12
2024
Q1 		$6.97M Buy
1,036,667
+69,919
+7% +$432K 1.93% 19
2023
Q4 		$5.68M Buy
966,748
+315,376
+48% +$2.42M 1.69% 22
2023
Q3 		$6.35M Buy
651,372
+31,372
+5% +$372K 1.93% 19
2023
Q2 		$7.34M Buy
620,000
+40,736
+7% +$467K 2.27% 13
2023
Q1 		$6.25M Buy
579,264
+400,264
+224% +$5.12M 2.58% 13
2022
Q4 		$2.07M Sell
179,000
-427,608
-70% -$5.3M 0.59% 52
2022
Q3 		$9.05M Sell
606,608
-214,346
-26% -$2.94M 3.06% 8
2022
Q2 		$7.41M Buy
820,954
+247,255
+43% +$1.69M 2.28% 14
2022
Q1 		$4.3M Sell
573,699
-277,236
-33% -$1.93M 1.78% 15
2021
Q4 		$7.3M Buy
850,935
+173,035
+26% +$1.5M 2.96% 9
2021
Q3 		$5.7M Buy
677,900
+479,655
+242% +$3.68M 3.22% 7
2021
Q2 		$1.61M Buy
198,245
+78,245
+65% +$661K 0.72% 52
2021
Q1 		$1.05M Sell
120,000
-115,066
-49% -$1.11M 0.57% 53
2020
Q4 		$2.64M Buy
+235,066
New +$2.58M 1.53% 24

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Silverarc Capital Management's COGT Position: Q2 2026 in Review

Silverarc Capital Management reduced its Cogent Biosciences (COGT) stake by 2.5% in Q2 2026, selling an estimated $1.17M and leaving 1,280,707 shares worth $49.6M. The position accounts for 5.15% of the portfolio, ranked #3.

Silverarc Capital Management first reported a position in COGT in Q4 2020 and has held it in 21 quarters since. The position peaked at $50.6M in Q1 2026. 322 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Silverarc Capital Management held 1,280,707 shares of Cogent Biosciences worth $49.6M as of Q2 2026.
  • Silverarc Capital Management sold 33,482 Cogent Biosciences shares in Q2 2026, an estimated $1.17M.
  • Cogent Biosciences made up 5.15% of Silverarc Capital Management's portfolio in Q2 2026, its #3 holding.
  • Silverarc Capital Management first reported a position in Cogent Biosciences in Q4 2020 and has held it in 21 quarters since.
  • Silverarc Capital Management's Cogent Biosciences position peaked at $50.6M in Q1 2026.
  • 322 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.